The FDA has accepted a brand new drug utility for relacorilant as a therapy for sufferers with platinum-resistant ovarian most cancers.
The U.S. Meals and Drug Administration (FDA) has accepted a brand new drug utility (NDA) for relacorilant as a therapy for sufferers with platinum-resistant ovarian most cancers.
The event was introduced in a information launch issued by Corcept Therapeutics, the commercial-stage firm behind relacorilant. In accordance with the information launch, the FDA has assigned a prescription drug consumer charge act of July 11, 2026, which means the company should reply to the applying by then.
“The FDA’s acceptance of our NDA brings us nearer to providing a much-needed therapy choice to sufferers with this dire illness,” mentioned Dr. Joseph Belanoff, Corcept’s Chief Govt Officer, in an announcement included within the information launch. “Relacorilant has the potential to redefine how platinum-resistant ovarian most cancers is handled.”
Relacorilant, as defined by the Nationwide Most cancers Institute on its web site, binds to and blocks glucocorticoid receptor proteins, lowering the unfavourable results ensuing from extra ranges of endogenous glucocorticoids resembling these seen when tumors overproduce glucocorticoids. Moreover, inhibition with the drug is meant to inhibit the proliferation of glucocorticoid receptor-overexpressing most cancers cells.
The NDA from Corcept is supported by optimistic information from the part 3 ROSELLA and part 2 scientific trials the place sufferers who had been handled with relacorilant plus nab-paclitaxel chemotherapy noticed enhancements in progression-free survival and general survival versus sufferers who acquired chemotherapy monotherapy, in response to the information launch.
The corporate acknowledged that the drug was well-tolerated per its identified security profile.
Extra Relacorilant Medical Trial Outcomes from ROSELLA
Relacorilant, as beforehand reported by CURE, within the ROSELLA scientific trial was related to a 30% decrease danger of illness development for sufferers handled with relacorilant and nab-paclitaxel versus those that acquired nab-paclitaxel alone, with median progression-free survival instances of 6.5 months versus 5.5 months. Moreover, an interim general survival evaluation confirmed a big enchancment with relacorilant, with a median of 16 months in contrast with 11.5 months for sufferers who acquired nab-paclitaxel alone.
The analysis continues. BELLA, a part 2 scientific trial evaluating the efficacy and security of the routine relacorilant plus nab-paclitaxel and Avastin (bevacizumab) amongst sufferers with superior, epithelial ovarian, main peritoneal or fallopian-tube most cancers, has been launched and is at present recruiting sufferers, in response to its itemizing on clinicaltrials.gov.
BELLA is a part 2, single-arm, open-label examine to judge the effectiveness and security of intermittent dosing of relacorilant together with nab-paclitaxel and Avastin amongst sufferers with ovarian most cancers, in response to the itemizing. With a deliberate eventual enrollment of roughly 90 sufferers, the trial has an estimated main completion date of August 2026, adopted by a examine completion date of December 2026, in response to the itemizing.
Platinum-resistant most cancers, as defined by the Nationwide Most cancers Institute on its web site, is most cancers that responds at first to medicine that comprise platinum, such because the chemotherapies cisplatin and carboplatin, however then comes again inside a sure window of time — within the case of ovarian most cancers, if the illness comes again inside six months after therapy, it’s thought-about to be platinum resistant.
Platinum-resistant ovarian most cancers, in response to information offered within the Asian Pacific Journal of Most cancers Prevention, is skilled by roughly 20% to 30% of sufferers, with a median general survival of roughly 12 to 18 months.
It’s estimated that in the USA in 2025, roughly 20,890 girls will obtain a brand new prognosis of ovarian most cancers and about 12,730 girls will die from the illness, in response to statistics offered by the American Most cancers Society.
References
- “FDA Recordsdata Corcept’s New Drug Software for Relacorilant as a Remedy for Sufferers with Platinum-Resistant Ovarian Most cancers,” information launch, Sept. 10, 2025; https://ir.corcept.com/news-releases/news-release-details/fda-files-corcepts-new-drug-application-relacorilant-treatment-0
- “Relacorilant,” Nationwide Most cancers Institute; https://www.most cancers.gov/publications/dictionaries/cancer-drug/def/relacorilant
- “Relacorilant Plus Chemo Meets Main Aim in Ovarian Most cancers Trial,” CURE, March 31, 2025; https://www.curetoday.com/view/relacorilant-plus-chemo-meets-primary-goal-in-ovarian-cancer-trial
- “BELLA Medical Trial Initiated in Platinum-Resistant Ovarian Most cancers,” CURE, April 7, 2025; https://www.curetoday.com/view/bella-clinical-trial-initiated-in-platinum-resistant-ovarian-cancer
- “Relacorilant in Mixture With Nab-paclitaxel and Bevacizumab in Superior, Epithelial Ovarian, Main Peritoneal, or Fallopian-Tube Most cancers;” https://clinicaltrials.gov/examine/NCT06906341?cond=%22Peritonealpercent20Neoplasmspercent22&aggFilters=standing:notpercent20rec&rank=1#study-overview
- “Platinum resistant most cancers,” Nationwide Most cancers Institute; https://www.most cancers.gov/publications/dictionaries/cancer-terms/def/platinum-resistant-cancer
- “Outcomes and Prognostic Elements of Sufferers with Platinum- Resistant or Refractory Epithelial Ovarian Most cancers, Fallopian Tube Most cancers and Peritoneal Most cancers,” Asian Pacific Journal of Most cancers Prevention; https://journal.waocp.org/article_90588.html
- “Key Statistics for Ovarian Most cancers,” American Most cancers Society; https://www.most cancers.org/most cancers/varieties/ovarian-cancer/key-statistics.html
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
